Aim: This study aimed to compare plasma copeptin levels, the c-terminal of provasopressin, between individuals with bipolar disorder (BD) and healthy controls and to assess the relation between copeptin and metabolic parameters.
Methods:
We measured plasma levels of copeptin in individuals with BD (n = 55) and healthy controls (n = 21). Information related to psychiatric/medical history, as well as to metabolic comorbidities and laboratorial parameters was also captured. Insulin resistance and β-cell function in basal state were calculated from fasting plasma glucose and C-peptide using the HOMA2 calculator. Impaired glucose metabolism was defined as pre-diabetes or type 2 diabetes mellitus. Copeptin, adiponectin, and leptin plasma levels were determined by enzyme-linked immunosorbent assay.
Results: Plasma copeptin levels were lower in individuals with BD, relative to healthy controls (P < 0.001). There were significant interactions between BD and plasma copeptin on β-cell function (rate ratio [RR] = 1.048; P = 0.030) and on leptin levels (RR = 1.087; P = 0.012), indicating that there was a positive correlation between these markers in the BD group, but a negative one in healthy controls. Finally, in individuals with BD only, the association between β-cell function, body mass index (RR = 1.007; P < 0.001), and insulin resistance (RR = 1.001; P = 0.037) was moderated by copeptin levels.
Conclusion:
Copeptin levels were lower in individuals with BD than in healthy controls. There were differential associations between copeptin and metabolic parameters within the BD and healthy control subgroups, suggesting an association between abnormal copeptin and metabolic dysregulation only in the BD population.
I
MPAIRMENT IN STRESS response systems has long been recognized as a core feature of psychiatric disorders, across diagnostic categories. 1 Replicated evidence indicates a prominent role of it in bipolar disorder (BD) pathophysiology and phenomenology. [1] [2] [3] [4] Psychosocial stress is a wellestablished trigger of mood episodes and stressful life events are amongst the most robust predictors of illness onset and relapse. [5] [6] [7] Abnormalities in stress response mediators, such as the hypothalamic-pituitary-adrenal (HPA) axis, have also been reliably demonstrated (e.g., cortisol secretion dysregulation, increased reactivity in response to psychosocial stressor). 3, [8] [9] [10] A robust body of evidence indicates that metabolic comorbidities (e.g., obesity, type 2 diabetes mellitus [T2DM], and dyslipidemia) are highly prevalent in individuals with mental disorders, including, but not limited to, the BD population. [11] [12] [13] [14] [15] [16] Convergent evidence indicates that metabolic comorbidities adversely affect BD outcomes. 17, 18 For instance, obesity, insulin resistance, and T2DM are associated with an unfavorable course of BD, characterized by a predominance of depressive features, treatment resistance, and functional disability. [19] [20] [21] [22] [23] [24] The involvement of HPA axis dysregulation in metabolic disorders etiopathology is widely recognized, as studies have reported an association between abdominal adiposity, impaired glucose homeostasis, and abnormal activation of the HPA axis. [25] [26] [27] [28] [29] [30] [31] It has been proposed that abnormalities in the stress response system are shared mechanisms that subserve the co-occurrence of metabolic disorders and BD. 18, 32, 33 Nevertheless, the mechanisms linking stress exposure and metabolic changes remain largely unknown.
Arginine vasopressin (AVP) is a pleiotropic hormone that regulates the hypothalamic stimulation of the HPA axis, facilitating the effects of the corticotrophin-releasing hormone. 34, 35 There are reports of abnormal peripheral AVP levels in individuals with BD; [36] [37] [38] however, the rapid biodegradation of AVP in the periphery (i.e., within minutes) confounds the interpretation of study results. 39 Copeptin is a cleavage product of the C-terminal part of the AVP precursor that is produced in equimolar amounts with AVP. In contrast to AVP, copeptin is stable and has a long half-life, thus, it is considered to be a clinically useful surrogate of AVP and provides a reliable correlate of cortisol secretion. [39] [40] [41] [42] [43] In fact, evidence has indicated that plasma copeptin levels are associated with psychosocial stress and HPA axis activation, [41] [42] [43] without the main limitation of saliva cortisol measurements, such as the estimation of HPA activation only in a short time before assessment. In fact, copeptin levels seem to be altered even several months or years after the stressor. 44 Although peripheral copeptin has been considered a promising biomarker, it was never measured in individuals with BD.
This study primarily aimed to compare plasma copeptin levels between individuals with BD and healthy controls and, secondarily, to determine the relation between copeptin levels and metabolic parameters. We hypothesized that: (i) plasma copeptin levels would be higher in individuals with BD, relative to healthy controls; (ii) copeptin levels would be associated with metabolic parameters, being higher in individuals with obesity or impaired glucose metabolism (IGM); and (iii) copeptin levels would mediate the difference in metabolic parameters between participants with BD and healthy controls.
METHODS

Study population and clinical assessment
Patients (n = 55) with BD type I/II (89% type 1 and 11% type 2) were recruited from the Vila Maria Outpatient Clinic in São Paulo, Brazil. A comparison group of healthy volunteers (n = 21) was also recruited. This study was approved by the local ethics committee and all subjects provided written informed consent before any study procedure. Psychiatric diagnosis was confirmed with the Structured Clinical Interview for DSM-IV (SCID-I). Manic and depressive symptoms were assessed using the Young Mania Rating Scale (YMRS) and the Hamilton Depression Rating Scale (HDRS), respectively. All subjects provided medical history, including lifetime use of any medication. Body mass index (BMI) was also measured using the formula BMI = weight (kg)/height (m) 2 . The healthy volunteers comparison group was screened for psychiatric disorders using SCID-I. Healthy subjects had not been prescribed psychotropic medication, and had no history of major psychiatric disorders, dementia, or intellectual disability. Exclusion criteria included presence of unstable or acute medical conditions, use of antiinflammatory medications, and pregnancy or breastfeeding.
Metabolic and laboratorial assessment
Whole blood samples were obtained from all participants. All samples were collected after a 12-h fast. Laboratorial metabolic parameters were measured immediately in a single laboratory with the same assay. Insulin resistance and β-cell function in the basal state were calculated from fasting plasma glucose and C-peptide using the HOMA2 calculator (http://www.dtu.ox.ac.uk). 45 IGM was defined as pre-diabetes or T2DM. T2DM diagnosis was based on previous diagnosis by a physician and/or use of antidiabetic medication (e.g., metformin, pioglitazone, insulin). Pre-diabetes was defined according to the American Diabetes Association criteria: fasting glucose levels between 100 and 125 mg/dL or glycated hemoglobin (Hb1Ac) between 5.7% and 6.4%. 46 Dyslipidemia diagnosis was based on previous diagnosis by a physician, use of hypolipidemic medication (e.g., statins), and/or abnormal laboratorial parameters. 47 Blood collected in EDTA tubes was kept in ice until processing; for plasma isolation, EDTA tubes were centrifuged at 280 g for 5 min in a refrigerated centrifuge, aliquoted, and kept at −80 C until further analyzed. Copeptin, adiponectin, and leptin plasma levels were determined by enzyme-linked immunosorbent assay (ELISA) kit, according to the manufacturer's instructions (Cloud-Clone Corporation, Katy, TX, USA, ref. E90365Hu; EMD Millipore Corporation, Billerica, MA, USA, Cat. #EZHADP-61K and #EZHL-80SK, respectively). Blinding procedures were used for staff responsible for analyses. Optical density was read with a microtiter plate photometer at 450 nm. Concentration was determined by interpolation from standard curves prepared with standard samples supplied by the manufacturer and expressed in μg/mL or ng/mL. Samples were run in duplicate and if the coefficient of variation between the replicates was higher than 10%, the sample was repeated.
Statistical analyses
For statistical analysis, SPSS for Windows (17.0; Chicago, IL, USA) was used. For the comparison of the demographic and clinical data, the independent samples t-test was used for quantitative variables and the χ 2 -test was used for categorical variables. Generalized linear models were used to assess the relation between copeptin levels, BD diagnosis, and metabolic comorbidities, adjusting for age and sex. As the outcomes (e.g., copeptin levels) had a positively skewed distribution (many low values and few higher values), we used a model with a gamma distribution and log-link function. Moderating effects were assessed by adding the product term (i.e., IGM × BD) to the tested models. Due to the non-linearity of the models, the estimated β coefficients created by the model were transformed into rate ratio (RR) estimates.
RESULTS
Sample characteristics
The mean age was 42.13 years (SD 11.27); 57 participants were female (75.0%) and 45 (59.2%) were Caucasian. The mean number of years of education was 11.35 (SD 3.53). There was no difference between patients and controls in age, sex, ethnicity, or years of education. The mean BMI was 28.19 kg/ m 2 (SD 5.23) and 22 (28.9%) subjects were obese (BMI ≥ 30 kg/m 2 ). Nineteen subjects (25.0%) used tobacco, 22 (28.9%) used alcohol, 48 individuals (63.2%) had a diagnosis -clinical or laboratorialof dyslipidemia, and 31 (40.8%) had IGM. Individuals with BD were significantly less likely to use alcohol; they also had higher mean BMI, and higher rates of obesity, tobacco use, and IGM, but the differences were not significant (Table 1) .
Copeptin levels, clinical and demographic characteristics
There was no correlation between copeptin levels and age (r = −0.137, P = 0.239) or years of education (r = −0.064, P = 0.609). Copeptin levels were lower in female participants (P = 0.002). There was no significant effect of ethnicity (P = 0.957). Moreover, there was no correlation between copeptin levels and BMI (r = −0.062, P = 0.606), or effect of tobacco use (P = 0.919) or alcohol use (P = 0.731).
There was no correlation between copeptin levels and YMRS score (r = −0.128, P = 0.273) or HDRS score (r = −0.130, P = 0.266). In individuals with BD, mood state did not affect copeptin levels (P = 0.760). Copeptin levels were not affected by the use of anticonvulsants (P = 0.488), lithium (P = 0.958), second-generation antipsychotics (P = 0.827), first-generation antipsychotics (P = 0.806), or antidepressants (P = 0.861).
Between-group differences
Unadjusted comparison indicated that copeptin levels were lower in individuals with BD, relative to healthy controls (mean 7.37, SD 4.72 vs mean 13.25, SD 5.87; Z = 3.932, P < 0.001) (Fig. 1) . A generalized linear model that included age and sex as covariates indicated that the difference between individuals with BD and healthy controls was still significant (RR = 0.614, P = 0.001). Sex-stratified analysis showed that between-group differences remained significant in female (P = 0.003) and male participants (P = 0.003) (Fig. 2b) . After adjustment for medication use, classified based on class (e.g., second-generation antipsychotics, anticonvulsants), lower copeptin levels in the BD group remained significant (RR = 0.667, P = 0.050), whereas no specific medication had a significant effect (all P-values > 0.05). Further adjustment for alcohol and tobacco use showed that the effect of BD diagnosis remained significant (RR = 0.515, P < 0.001). Of note, individuals with BD had lower levels of copeptin regardless of lithium use (P = 0.003 vs P = 0.001) and regardless of secondgeneration antipsychotics use (P = 0.002 vs P = 0.012). Table 2 shows comparisons of laboratorial metabolic parameters between individuals with BD and healthy controls, after adjustment for age and sex. Individuals with BD, relative to healthy controls, had higher levels of plasma insulin, C-peptide, homeostasis model assessment for insulin resistance (HOMA2-IR), homeostasis model assessment for β-cell function (HOMA2-%β), very low-density lipoprotein (VLDL) cholesterol, and triglycerides. As for confounders, there were associations between use of lithium and higher C-peptide (P = 0.018), HOMA2-IR (P = 0.018), and VLDL (P = 0.013); use of anticonvulsants and higher VLDL (P = 0.007) and triglycerides (P = 0.001); as well as of use of alcohol and lower plasma insulin (P = 0.012). Smoking and use of antipsychotics or antidepressants did not impact any of the laboratorial metabolic parameters. After removing individuals with BD that were on lithium from the analyses, the association between BD and higher levels of C-peptide (P = 0.036), HOMA2-IR (P = 0.032), and VLDL (P = 0.029) were still significant. Removal of participants on anticonvulsants also did not alter the association between BD and higher VLDL (P = 0.041) and triglycerides (P = 0.041). When the analysis was restricted to individuals who used (P = 0.767) or did not use alcohol (P = 0.770), the difference in insulin levels between individuals with BD and healthy controls was non-significant.
Copeptin and laboratorial metabolic parameters
Copeptin levels were higher in individuals with dyslipidemia (mean 8.61, SD 4.66 vs mean 5.75, SD 2.63; P = 0.028), whereas there was no effect of IGM (P = 0.563). Moreover, there were somewhat different patterns of association between plasma copeptin and laboratorial metabolic parameters between participants with BD and healthy controls (Table 3) , wherein plasma copeptin was only associated with high-density lipoprotein (HDL) cholesterol in the healthy controls group; and with fasting glucose, HOMA2-%β, and leptin in the BD group. These differences provided the impetus to explore whether differences in metabolic parameters between individuals with BD and healthy controls could be partially explained by differences in plasma copeptin levels. We first analyzed differences between individuals with BD and healthy controls in models including dyslipidemia and IGM, also adjusting for age and sex. Differences between subjects with BD and healthy controls were significant in individuals with dyslipidemia (P = 0.005), as well as in those without (P = 0.009) (Fig. 1c) . Higher copeptin levels in individuals with dyslipidemia were found in the BD (P = 0.023) and healthy controls subgroups (P = 0.021). We observed lower levels of copeptin in subjects with BD, compared to healthy controls: in individuals with IGM (P = 0.003) as well as in those without (P = 0.001). There was no effect of IGM in individuals with BD (P = 0.122) or healthy controls (P = 0.143).
We also observed that the strength of the association between BD and higher HOMA2-%β was greater in a model that included plasma copeptin (RR = 1.424, P = 0.002), when compared to a model that did not include copeptin (RR = 1.267, P = 0.027). There were interactions between BD and plasma copeptin on HOMA2-%β levels (RR = 1.048, P = 0.030), suggesting that the correlation between copeptin and HOMA2-%β was stronger in BD participants, compared to healthy controls (Fig. 2a) . There was also a significant interaction between BD and plasma copeptin on leptin levels (RR = 1.087; P = 0.012), indicating that there was a positive correlation between these markers in the BD subgroup, but a negative one in healthy controls (Fig. 2b ). There were no significant interactions for fasting glucose (RR = 0.976, P = 0.140) and HDL cholesterol (RR = 1.015, P = 0.281). As, under physiological conditions, β-cell function is strongly associated with BMI and insulin resistance, we further investigated if BD diagnosis and plasma copeptin moderated the association between these variables. All models were adjusted for age and sex. In the whole sample, after adjustment for age, HOMA2-%β was correlated with BMI (r = 0.364, P = 0.003) and HOMA2-IR (r = 0.522, P < 0.001). The association between BMI and HOMA2-%β was moderated by copeptin levels (RR = 1.007; P < 0.001), indicating a stronger correlation with increasing copeptin values. There was a trend for a moderating effect of BD diagnosis (RR = 0.965, P = 0.066). Moreover, the moderating effect of copeptin was further moderated by a diagnosis of BD, as it was significant in the BD group (P = 0.007), but not in the healthy controls group (P = 0.997) (Fig. 3) . Similarly, the association between HOMA2-%β and HOMA2-IR was moderated by a diagnosis of BD (RR = 0.991, P = 0.002), indicating a weaker correlation in the BD subgroup; and positively by copeptin levels (RR = 1.001; P = 0.037), indicating a stronger correlation with increasing copeptin values. The moderating effect of copeptin was also further moderated by a diagnosis of BD, being significant in the BD group (P = 0.005), but not in the healthy controls group (P = 0.949).
DISCUSSION
The results of this study showed that: (i) contrary to our a priori hypothesis, plasma copeptin levels were lower in individuals with BD, relative to healthy controls; (ii) dyslipidemia was associated with higher copeptin levels, whereas copeptin was correlated with HDL cholesterol in healthy controls and with fasting glucose, HOMA2-%β, and leptin in the BD group; but (iii) differences in copeptin levels between BD participants and healthy controls were not mediated by metabolic comorbidities, insofar as copeptin levels were higher in participants with dyslipidemia, regardless of BD diagnosis.
Meta-analytical studies have documented a hyperactivity of the HPA axis in BD, characterized by higher basal levels of cortisol, adrenocorticotrophic hormone (ACTH), and increased response to pharmacological and/or psychosocial stress.
3,10 Activation of AVP receptors in the neurohypophysis stimulates ACTH production, synergistically with corticotrophin-releasing hormone. [48] [49] [50] Indeed, there is consistent evidence that, in healthy volunteers, acute stress-induced increase in cortisol levels is associated with increase in copeptin levels. 42, 43, 51, 52 Nonetheless, a study that assessed copeptin levels in major depressive disorder, wherein findings on HPA axis hyperactivity have been similar, did not observe differences in copeptin levels between participants with depression and healthy controls or correlations between copeptin, cortisol, and ACTH. 53 Evidence indicates that AVP expression is highly sensitive to feedback inhibition by glucocorticoids, [54] [55] [56] which is modulated by type and intensity of stress, as well as by an interaction of glucocorticoids with neurotransmitters and neuropeptides activated by stress. 54, 57 Elevated basal levels of AVP have been documented in animal models of chronic stress 58, 59 and it has been proposed that this response has the function of preserving HPA axis responsiveness in the high glucocorticoid milieu of chronic stress. 54 Therefore, it is possible to hypothesize that the lower levels of copeptin observed in individuals with BD may represent a maladaptive response and contribute to the overall dysregulation of the stress response system documented in this population. 3, 10 It is also possible that there is a primary disturbance of the AVP system in BD, insofar as studies have documented an association between functional polymorphisms of the AVP receptor gene and mood disorders. 60, 61 Conversely, one study reported lower levels of AVP in individuals with BD and first-degree relatives, which were highly familial. 38 Differences in copeptin levels between individuals with BD and healthy controls were independent from possible confounding factors. Consistent with previous reports, we observed lower levels of copeptin in female participants, but comparisons stratified by sex continued to show lower levels of copeptin in the BD population. Adjustment for medications, including sub-analyses of the two classes of medications (i.e., lithium and second-generation antipsychotics) that have been most frequently involved in AVP and HPA axis abnormalities, 3, 37 did not alter the results.
Results showed no association between BMI, IGM, and serum copeptin levels in our sample, but there were significantly higher levels in participants with dyslipidemia, which has been previously reported. [62] [63] [64] The lack of association with obesity and diabetes in the whole sample may be -at least partially -explained by the differential associations between laboratorial metabolic parameters and plasma copeptin that were observed. Beta-cell function was significantly increased in patients, relative to controls, whereas there was a trend for elevated leptin. Despite lower mean levels of copeptin in individuals with BD, there was actually a stronger association between copeptin, increased β-cell function, and leptin levels in this subgroup. Copeptin has been associated with abnormal fasting glucose, higher insulin, and Hb1Ac levels, as well as increased long-term risk of T2DM in the general population. [62] [63] [64] Individuals with elevated copeptin were shown to have a two-to threefold excess risk of T2DM, independently of baseline fasting glucose and other clinical factors, including obesity. 65 Although an impairment in β-cell function has been traditionally linked to T2DM, 66 there are reports of compensatory, elevated β-cell function associated with an increased risk of T2DM. [67] [68] [69] Furthermore, it has been shown that the administration of glucocorticoids can stimulate β-cell function, 70, 71 suggesting that the association between copeptin and increased HOMA2-%β values may be mediated by HPA axis activation. This is the first study to report a correlation between copeptin and leptin. Animal studies have reported that intracerebroventricular leptin administration activates the HPA axis and increases plasma AVP. 72, 73 Conversely, the administration of AVP in humans was shown to suppress plasma leptin concentrations, which may be the result of a negative feedback regulatory system. 74, 75 Interestingly, there was also a modifying effect of copeptin on the association between β-cell function, BMI, and insulin resistance in individuals with BD. Adiposity is a robust predictor of insulin resistance and increased β-cell function, 76, 77 which was indeed observed in the control group. However, in individuals with BD, these relationships were modified by copeptin levels. Metabolic pathways are highly intricate and regulation of bodyweight and glucose/insulin homeostasis involves multiple interacting mechanisms. [78] [79] [80] BD has been associated not only with multiple metabolic comorbidities (e.g., T2DM and obesity), but also with alterations in several components of hormonal and regulatory signaling (e.g., adipokines, incretins, and cytokines). [81] [82] [83] [84] Our results suggest that variations in the AVP system, related or not to HPA axis function, may be involved in, and/or be impacted by, metabolic dysfunction.
Conversely, the AVP system has also been implicated in the regulation of metabolic systems. Insulin-induced hypoglycemia has been documented to increase serum AVP and copeptin. 51, 85, 86 Paraventricular neurons of the hypothalamus and in the supraoptical nucleus that synthesize and release AVP and copeptin also express glucose and insulin receptors. 87 Evidence indicates that glucose and insulin regulate AVP release. 87, 88 A recent study reported that central insulin signal modulated HPA and AVP responsivity to stress, wherein AVP hypothalamic expression was significantly reduced in neuronal insulin receptor knockout mice (i.e., brain-specific knockout of insulin receptor-NIRKO), relative to controls, during restrain stress. 88 There is no direct evidence of abnormal central insulin signaling in BD, but there is consistent evidence that peripheral insulin resistance is associated with central insulin dysregulation, [89] [90] [91] suggesting that the metabolic dysregulation and abnormal copeptin levels described herein may be, in fact, mechanistically inter-related.
Limitations of our study herein include the small sample size, which limits the understanding of the associations between copeptin and metabolic parameters. All individuals with BD were prescribed medication, which could affect our findings. Notwithstanding, we did not find any significant effects of psychotropic medications. Our sample was heterogeneous, with a high proportion of female participants, as well as individuals in different mood states; therefore the generalizability of the findings is limited. Larger and prospective studies would be required to confirm and expand the findings described herein.
In summary, our study, to the best of our knowledge, is the first to report on copeptin in a wellcharacterized sample of adults with BD. We determined that copeptin levels were lower in individuals with BD: an effect that remains significant after adjusting for relevant confounding factors. We also documented an association between copeptin and metabolic parameters, with different patterns in the BD and healthy control subgroups, suggesting an association between abnormal copeptin and metabolic dysregulation in the BD population. Our results suggest that abnormalities in stress response substrates are a common nexus of BD and metabolic comorbidity and that copeptin could be explored as a potentially useful mediator of multisystemic abnormality in BD.
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